Abpro Holdings (ABPO) Change in Accured Expenses (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Change in Accured Expenses came in at -$512000.0 in Q1 2026, down 764.94% YoY from $77000.0 in Q1 2025, and down 289.63% on a QoQ basis from $270000.0 in Q4 2025.
Abpro Holdings (ABPO) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Change in Accured Expenses data on file, last reported at -$512000.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 764.94% year-over-year to -$512000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$392000.0 (down 188.09% YoY) and the FY2025 annual result came in at $197000.0, down 47.88% from the prior year.
- Change in Accured Expenses fell to -$512000.0 in Q1 2026, from $270000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.0 million in Q4 2023 to a low of -$1.1 million in Q3 2023.
- A 5-year average of $105198.8 and a median of $240000.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2025 — Change in Accured Expenses surged 670.0% — and 2026, when it sank 764.94%.
- Tracing ABPO's Change in Accured Expenses over 5 years: stood at $347463.0 in 2022, then surged by 191.26% to $1.0 million in 2023, then tumbled by 117.09% to -$173000.0 in 2024, then soared by 256.07% to $270000.0 in 2025, then tumbled by 289.63% to -$512000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$512000.0 (Q1 2026), $270000.0 (Q4 2025), and -$390000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -512,000.00 |
| Mar 31, 2026 | -512,000.00 |
| Dec 31, 2025 | 270,000.00 |
| Dec 31, 2025 | 270,000.00 |
| Sep 30, 2025 | -390,000.00 |
| Sep 30, 2025 | -390,000.00 |
| Jun 30, 2025 | 240,000.00 |
| Jun 30, 2025 | 240,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Dec 31, 2024 | -173,000.00 |
| Dec 31, 2024 | -173,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2023 | 1.01 Mn |